Brazilian pharmaceutical company Eurofarma announced the launching of Eurofarma Ventures, a corporate venture capital arm that will invest up to$100 million in biotech startups.
Beyond this fund, the company’s innovation arm includes Eurolab, Latin America’s largest pharmaceutical innovation group, which has 600 researchers working on over 400 new drug projects, as well as an organic synthesis laboratory dedicated to the discovery of new molecules.
Founded in 1972, Eurofarma is the first multinational pharmaceutical company with 100% Brazilian capital. In 2022, it generated net sales of $1,6 billion and employed more than 11,000 people. Eurofarma operates in 22 countries, offers over 430 products, and serves 30 medical specialties representing 66% of the total market.
Read more on DF Sud
